Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

94.96 +3.74 (+4.10%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
74 75 Next >
News headline image
Momentum in Healthcare and Banking to Persist in 2026 as AstraZeneca and Citigroup Lead the Charge
As the global markets open for the first week of 2026, a clear narrative has emerged: the "recovery plays" of 2025 have officially transformed into the "expansion leaders" of the new year. Following a... 
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls
Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s... 
Via MarketMinute
Topics Economy Intellectual Property World Trade
News headline image
Is IonQ Stock a Buy Now? ↗
This rising star in quantum computing is a high-risk but potentially high-reward play. 
Via The Motley Fool
News headline image
The Motley Fool Interviews MichaelAaron Flicker: Hacking the Human Mind ↗
MIchaelAaron Flicker is the co-author of "Hacking The Human Mind: The Behavioral Science Secrets Behind 17 of the World's Best Brands." 
Via The Motley Fool
News headline image
AstraZeneca (NASDAQ:AZN) Shows Strong Technical Setup for Potential Breakout ↗
AstraZeneca (AZN) shows a top technical rating and a high-quality consolidation pattern, signaling a potential breakout opportunity for technical traders. 
Via Chartmill
News headline image
The Pfizer Pivot: A Deep-Dive into PFE’s 2025 Financial Recovery and Strategic Rebirth
As of today, December 22, 2025, Pfizer Inc. (NYSE: PFE) stands as a case study in corporate reinvention and the brutal reality of the post-pandemic "hangover." Once the darling of the global healthcare... 
Via PredictStreet
Topics Economy Intellectual Property
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer
From AstraZeneca
Via Business Wire
News headline image
Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗
The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief. 
Via Stocktwits
Topics Government World Trade
News headline image
3 Absurdly Cheap Stocks You Can Buy For Less than $100 Right Now ↗
The stocks listed here trade at forward earnings multiples of less than 18. 
Via The Motley Fool
News headline image
Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗
The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing. 
Via Stocktwits
Topics Government World Trade
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
From AstraZeneca
Via Business Wire
News headline image
What to Watch With IonQ Stock in 2026 ↗
The New Year is shaping up to be an important one for this quantum computing stock. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH
From AstraZeneca
Via Business Wire
News headline image
Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension
From AstraZeneca
Via Business Wire
News headline image
US-UK Near Landmark Zero-Tariffs Pharma Deal, Announcement Expected Soon: Report ↗
The report states that the agreement between the U.S. and the U.K. is expected to be announced in the coming days. 
Via Stocktwits
Topics World Trade
News headline image
Biotech Bull ETF Surges To 20-Month High: Analysts Say Medicare’s Drug-Pricing Blow Is Softer Than Feared ↗
Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries. 
Via Stocktwits
Topics ETFs
News headline image
Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied ↗
Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the IRA. 
Via Investor's Business Daily
Topics Economy Government
News headline image
IMFINZI® approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca PLC-SPONS ADR (NASDAQ:AZN) Passes Key Quality Investing Screen for Long-Term Growth ↗
AstraZeneca (AZN) is a top-quality stock for long-term investors, showing strong revenue growth, high profitability, and solid cash flow generation. 
Via Chartmill
News headline image
Why AstraZeneca Stock Bumped Higher Today ↗
The company is wasting little time figuring out the particulars of a sweeping capital investment program. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth
From AstraZeneca
Via Business Wire
News headline image
FDA Approval Delivers Momentum For AstraZeneca's Rare Disease Portfolio ↗
AstraZeneca receives FDA approval for Koselugo to treat adults with NF1 and inoperable plexiform neurofibromas, backed by strong Phase 3 data. 
Via Benzinga
News headline image
Where Will IonQ Be in 10 Years? ↗
A lot can happen for this quantum computing leader over the next decade. 
Via The Motley Fool
News headline image
Johnson & Johnson Inks A $3.05 Billion Deal In Cancer Treatment ↗
Johnson & Johnson said Monday it's putting up $3.05 billion to buy privately held cancer player Halda Therapeutics. 
Via Investor's Business Daily
News headline image
IonQ (IONQ) Surges on Strong Revenue Outlook and Insider Confidence Amidst Quantum Computing Race
November 14, 2025 – Quantum computing pioneer IonQ (NYSE: IONQ) recently captured significant market attention, with its stock experiencing a notable 3.6% gain on November 5, 2025, driven by an... 
Via MarketMinute
Topics Intellectual Property
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Why AstraZeneca Stock Was a Winner Today ↗
The company inches closer to bringing a new drug to a very large addressable market. 
Via The Motley Fool
News headline image
AI’s Next Frontier: Key Stocks to Watch Amidst Market Shifts and Technological Leaps
The artificial intelligence (AI) sector is currently navigating a period of unprecedented dynamism, characterized by explosive technological advancements, massive capital inflows, and a palpable... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial ↗
AstraZeneca's Baxdrostat cut blood pressure by 14 mmHg in the Phase 3 Bax24 trial, showing strong efficacy and safety in resistant hypertension patients. 
Via Benzinga
News headline image
Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial
From AstraZeneca
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.